![](http://societe-cbp.ca/wp-content/uploads/2017/09/gilead1-300x143.jpg)
The American Association for the Study of Liver Diseases published findings that the ASK1 Inhibitor Selonsertib reduced liver fibrosis in stage 2-3 liver fibrosis. In late 2016 Gilead announced that Selonsertib was being tested with “
GS-9674″ an FXR agonist for PBC. Read more click here.